Protection of hamsters from mortality by reducing fecal moxifloxacin concentration with DAV131A in a model of moxifloxacin-induced Clostridium difficile colitis

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 10, 2017, Pages

  Burdet, Charles ^a,b   Sayah Jeanne, Sakina ^c   Nguyen, Thu Thuy ^a   Miossec, Christine ^c,e   Saint Lu, Nathalie ^c   Pulse, Mark ^d   Weiss, William ^d   Andremont, Antoine ^a,b   Mentré, France ^a,b   De Gunzburg, Jean ^c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b BICHAT HOSPITAL   (France)

^c Da Volterra   (France)

^d UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^e Vetoquinol France   (France)

Author keywords

Clostridium difficile infection; Hamster animal model; Mortality; Moxifloxacin; Prevention

Indexed keywords

ACTIVATED CARBON; DAV 131A; MOXIFLOXACIN; UNCLASSIFIED DRUG; CHARCOAL; QUINOLONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG FECES LEVEL; HAMSTER MODEL; MATHEMATICAL MODEL; MORTALITY RATE; NONHUMAN; PRIORITY JOURNAL; SYRIAN HAMSTER; ANIMAL; CHEMICALLY INDUCED; CLOSTRIDIUM INFECTION; DISEASE MODEL; DOSE RESPONSE; DYSBIOSIS; GASTROINTESTINAL TRACT; HAMSTER; INTESTINE FLORA; MICROBIOLOGY; MORTALITY; PATHOGENICITY; PEPTOCLOSTRIDIUM DIFFICILE; PSEUDOMEMBRANOUS COLITIS;

ANIMALS; CHARCOAL; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; CRICETINAE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSBIOSIS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FLUOROQUINOLONES; GASTROINTESTINAL MICROBIOME; GASTROINTESTINAL TRACT;

EID: 85029764234     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00543-17     Document Type: Article

References (28)

1. Leffler DA, Lamont JT. 2015. Clostridium difficile infection. N Engl J Med 372:1539–1548. https://doi.org/10.1056/NEJMra1403772.
2. Lessa FC, Mu Y, Bamberg WM, Beldavs ZG, Dumyati GK, Dunn JR, Farley MM, Holzbauer SM, Meek JI, Phipps EC, Wilson LE, Winston LG, Cohen JA, Limbago BM, Fridkin SK, Gerding DN, McDonald LC. 2015. Burden of Clostridium difficile infection in the United States. N Engl J Med 372: 825– 834. https://doi.org/10.1056/NEJMoa1408913.
3. Dubberke ER, Olsen MA. 2012. Burden of Clostridium difficile on the healthcare system. Clin Infect Dis 55(Suppl 2):S88–S92. https://doi.org/10.1093/cid/cis335.
4. Miller BA, Chen LF, Sexton DJ, Anderson DJ. 2011. Comparison of the burdens of hospital-onset, healthcare facility-associated Clostridium difficile infection and of healthcare-associated infection due to methicillin-resistant Staphylococcus aureus in community hospitals. Infect Control Hosp Epidemiol 32:387–390. https://doi.org/10.1086/659156.
5. CDC. 2013. Antibiotic resistance threats in the United States, 2013. www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf. Accessed 6 July 2017.
6. Dethlefsen L, Relman DA. 2011. Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation. Proc Natl Acad Sci U S A 108(Suppl 1):S4554–S4561. https://doi.org/10.1073/pnas.1000087107.
7. Theriot CM, Young VB. 2015. Interactions between the gastrointestinal microbiome and Clostridium difficile. Annu Rev Microbiol 69:445–461. https://doi.org/10.1146/annurev-micro-091014-104115.
8. Leonard FC, Andremont AO, Tancrede CH. 1985. In vivo influence of three -lactam antibiotics on the intestinal microflora of man. A preliminary study in gnotobiotic mice. Prog Clin Biol Res 181:279–282.
9. Stiefel U, Pultz NJ, Harmoinen J, Koski P, Lindevall K, Helfand MS, Donskey CJ. 2003. Oral administration of -lactamase preserves colonization resistance of piperacillin-treated mice. J Infect Dis 188:1605–1609. https://doi.org/10.1086/379153.
10. Harmoinen J, Mentula S, Heikkila M, van der Rest M, Rajala-Schultz PJ, Donskey CJ, Frias R, Koski P, Wickstrand N, Jousimies-Somer H, Westermarck E, Lindevall K. 2004. Orally administered targeted recombinant -lactamase prevents ampicillin-induced selective pressure on the gut microbiota: a novel approach to reducing antimicrobial resistance. Antimicrob Agents Chemother 48:75–79. https://doi.org/10.1128/AAC.48.1.75-79.2004.
11. Tarkkanen AM, Heinonen T, Jogi R, Mentula S, van der Rest ME, Donskey CJ, Kemppainen T, Gurbanov K, Nord CE. 2009. P1A recombinant -lactamase prevents emergence of antimicrobial resistance in gut microflora of healthy subjects during intravenous administration of ampi-cillin. Antimicrob Agents Chemother 53:2455–2462. https://doi.org/10.1128/AAC.00853-08.
12. Kaleko M, Bristol JA, Hubert S, Parsley T, Widmer G, Tzipori S, Subramanian P, Hasan N, Koski P, Kokai-Kun J, Sliman J, Jones A, Connelly S. 2016. Development of SYN-004, an oral -lactamase treatment to protect the gut microbiome from antibiotic-mediated damage and prevent Clostridium difficile infection. Anaerobe 41:58 – 67. https://doi.org/10.1016/j.anaerobe.2016.05.015.
13. Kokai-Kun JF, Roberts T, Coughlin O, Sicard E, Rufiange M, Fedorak R, Carter C, Adams MH, Longstreth J, Whalen H, Sliman J. 2017. The oral -lactamase SYN-004 (ribaxamase) degrades ceftriaxone excreted into the intestine in phase 2a clinical studies. Antimicrob Agents Chemother 61:e02197-16. https://doi.org/10.1128/AAC.02197-16.
14. Pepin J, Saheb N, Coulombe MA, Alary ME, Corriveau MP, Authier S, Leblanc M, Rivard G, Bettez M, Primeau V, Nguyen M, Jacob CE, Lanthier L. 2005. Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 41:1254–1260. https://doi.org/10.1086/496986.
15. Khoder M, Tsapis N, Domergue-Dupont V, Gueutin C, Fattal E. 2010. Removal of residual colonic ciprofloxacin in the rat by activated charcoal entrapped within zinc-pectinate beads. Eur J Pharm Sci 41:281–288. https://doi.org/10.1016/j.ejps.2010.06.018.
16. Grall N, Massias L, Nguyen TT, Sayah-Jeanne S, Ducrot N, Chachaty E, de Gunzburg J, Andremont A. 2013. Oral DAV131, a charcoal-based adsorbent, inhibits intestinal colonization by -lactam-resistant Klebsiella pneumoniae in cefotaxime-treated mice. Antimicrob Agents Chemother 57:5423–5425. https://doi.org/10.1128/AAC.00039-13.
17. Price AB, Larson HE, Crow J. 1979. Morphology of experimental antibiotic-associated enterocolitis in the hamster: a model for human pseudomembranous colitis and antibiotic-associated diarrhoea. Gut 20: 467–475. https://doi.org/10.1136/gut.20.6.467.
18. Swanson RN, Hardy DJ, Shipkowitz NL, Hanson CW, Ramer NC, Fernandes PB, Clement JJ. 1991. In vitro and in vivo evaluation of tiacumicins B and C against Clostridium difficile. Antimicrob Agents Chemother 35:1108 –1111. https://doi.org/10.1128/AAC.35.6.1108.
19. Babcock GJ, Broering TJ, Hernandez HJ, Mandell RB, Donahue K, Boatright N, Stack AM, Lowy I, Graziano R, Molrine D, Ambrosino DM, Thomas WD, Jr. 2006. Human monoclonal antibodies directed against toxins A and B prevent Clostridium difficile-induced mortality in hamsters. Infect Immun 74:6339–6347. https://doi.org/10.1128/IAI.00982-06.
20. Barker RH, Jr, Dagher R, Davidson DM, Marquis JK. 2006. Review article: tolevamer, a novel toxin-binding polymer: overview of preclinical pharmacology and physicochemical properties. Aliment Pharmacol Ther 24: 1525–1534. https://doi.org/10.1111/j.1365-2036.2006.03157.x.
21. Burdet C, Nguyen TT, Saint-Lu N, Sayah-Jeanne S, Weiss W, Pulse M, Andremont A, Mentré F, de Gunzburg J. 2016. IDWeek 2016, New Orleans, LA, 26 to 30 October 2016, poster 2252.
22. Kurtz CB, Cannon EP, Brezzani A, Pitruzzello M, Dinardo C, Rinard E, Acheson DW, Fitzpatrick R, Kelly P, Shackett K, Papoulis AT, Goddard PJ, Barker RH, Jr, Palace GP, Klinger JD. 2001. GT160-246, a toxin binding polymer for treatment of Clostridium difficile colitis. Antimicrob Agents Chemother 45:2340–2347. https://doi.org/10.1128/AAC.45.8.2340-2347.2001.
23. Phillips ST, Nagaro K, Sambol SP, Johnson S, Gerding DN. 2011. Susceptibility of hamsters to infection by historic and epidemic BI Clostridium difficile strains during daily administration of three fluoroquinolones. Anaerobe 17:166–169. https://doi.org/10.1016/j.anaerobe.2011.03.015.
24. Burkhardt O, Borner K, Stass H, Beyer G, Allewelt M, Nord CE, Lode H. 2002. Single- and multiple-dose pharmacokinetics of oral moxifloxacin and clari-thromycin, and concentrations in serum, saliva and faeces. Scand J Infect Dis 34:898–903. https://doi.org/10.1080/0036554021000026963.
25. de Gunzburg J, Ducher A, Modess C, Wegner D, Oswald S, Dressman J, Augustin V, Feger C, Andremont A, Weitschies W, Siegmund W. 2015. Targeted adsorption of molecules in the colon with the novel adsorbent-based medicinal product, DAV132: a proof of concept study in healthy subjects. J Clin Pharmacol 55:10 –16. https://doi.org/10.1002/jcph.359.
26. FDA. 2008. Avelox label. https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021085s039,021277s033lbl.pdf. Accessed 6 July 2017.
27. National Research Council. 2011. Guide for the care and use of laboratory animals, 8th ed. National Academies Press, Washington, DC.
28. Kampougeris G, Antoniadou A, Kavouklis E, Chryssouli Z, Giamarellou H. 2005. Penetration of moxifloxacin into the human aqueous humour after oral administration. Br J Ophthalmol 89:628 – 631. https://doi.org/10.1136/bjo.2004.050054.